+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dementia Drugs Market by Drug Class, Distribution Channel, End User, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status - Global Forecast to 2030- Product Image
Dementia Drugs Market by Drug Class, Distribution Channel, End User, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status - Global Forecast to 2030- Product Image
Sale

Dementia Drugs Market by Drug Class, Distribution Channel, End User, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083640
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The dementia drugs market is experiencing significant transformation, driven by scientific innovation, evolving regulatory landscapes, and changing patient needs. For senior decision-makers, navigating this environment requires a clear understanding of market segmentation, regional trends, and the strategic moves of industry leaders.

Market Snapshot: Dementia Drugs Market Growth and Dynamics

The Dementia Drugs Market grew from USD 10.78 billion in 2024 to USD 11.96 billion in 2025. It is expected to continue growing at a CAGR of 10.47%, reaching USD 19.60 billion by 2030. Expanding patient populations, advances in neuroscience, and heightened interest from biopharma innovators drive ongoing development and commercialization across key global regions. This trajectory reflects a landscape where scientific discovery, regulatory scrutiny, and payer negotiations converge to shape investment strategies and competitive positioning.

Dementia Drugs Market: Scope & Segmentation Overview

This report provides a comprehensive exploration of the dementia drugs market, delivering actionable insights across all major dimensions. The market analysis is underpinned by detailed segmentation and an assessment of emerging technologies and regional influences.

  • Drug Class: Cholinesterase inhibitors (Donepezil, Galantamine, Rivastigmine); combination therapies (Donepezil and Memantine); NMDA receptor antagonists (Memantine)
  • Distribution Channel: Hospital pharmacy; online pharmacy; retail pharmacy; specialty pharmacy
  • End User: Clinics; home care settings; hospitals; long-term care facilities
  • Treatment Type: Combination therapy; monotherapy
  • Route Of Administration: Oral; transdermal
  • Patient Age Group: 65 to 74; 75 to 84; 85 and above; under 65
  • Disease Stage: Mild; moderate; severe
  • Patent Status: Branded; generic
  • Region: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: Biogen Inc.; Eisai Co., Ltd.; Eli Lilly and Company; Roche Holding AG; Novartis AG; H. Lundbeck A/S; AC Immune SA; Axsome Therapeutics, Inc.; Cassava Sciences, Inc.; Otsuka Pharmaceutical Co., Ltd.

Key Takeaways for Senior Decision-Makers

  • Innovative therapies are emerging that target a range of disease mechanisms beyond traditional symptomatic treatment, enabling precision medicine tailored to patient subgroups.
  • Digital health technologies, including wearable monitoring and remote cognitive assessment, are enhancing trial endpoints and patient engagement strategies.
  • Regulatory bodies are adapting with faster approval pathways and a higher emphasis on real-world evidence, reshaping global market entry and commercialization plans.
  • Changes in patient access models, such as the expansion of online and specialty pharmacy channels, are redefining how and where therapies are delivered.
  • Lifecycle management, partnerships, and strategic acquisitions are intensifying as companies aim to strengthen portfolios, accelerate time-to-market, and defend market share.
  • Understanding nuanced segmentation—including treatment settings, administration modes, and regional differences—remains critical for effective resource allocation and growth.

Tariff Impact: Navigating 2025 Policy Shifts in the U.S.

The introduction of new tariffs in the U.S. in early 2025 has impacted both the cost structure and supply strategies for dementia therapeutics. Manufacturers responding to increased production expenses are balancing between protecting affordability for payers and managing their own margins. Companies reliant on imported ingredients have adapted by exploring geographic diversification in manufacturing and by building inventory ahead of policy change, yet these approaches have their own financial and operational challenges. The broader effect has been accelerated conversations around localized supply chains and flexible procurement models, influencing long-term strategies for access and pricing.

Methodology & Data Sources

This market intelligence is based on a multi-layered research framework, including primary interviews with industry executives, clinicians, regulatory specialists, and payers, supported by secondary reviews of industry publications, clinical trial registries, and patent databases. Scenarios and quantitative analyses validate trends and provide an integrated perspective for segmentation and regional evaluation.

Why This Report Matters

  • Enables C-suite executives to benchmark competitive positioning and strategize for both current therapy portfolios and future pipeline assets in the dementia drugs market.
  • Delivers clarity on regional dynamics, distribution innovations, and technology integration necessary to inform investment, partnership, and business development decisions.
  • Empowers leadership to proactively manage risk and capture emerging opportunities by aligning with regulatory, payer, and policy trends globally.

Conclusion

This report delivers the clarity needed for leaders to navigate complex market and regulatory environments. It equips decision-makers to drive business results and adapt to the evolving challenges of dementia therapeutics.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dementia Drugs Market, by Drug Class
8.1. Introduction
8.2. Cholinesterase Inhibitors
8.2.1. Donepezil
8.2.2. Galantamine
8.2.3. Rivastigmine
8.3. Combination Therapies
8.3.1. Donepezil And Memantine
8.4. Nmda Receptor Antagonists
8.4.1. Memantine
9. Dementia Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.5. Specialty Pharmacy
10. Dementia Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care Settings
10.4. Hospitals
10.5. Long-Term Care Facilities
11. Dementia Drugs Market, by Treatment Type
11.1. Introduction
11.2. Combination Therapy
11.3. Monotherapy
12. Dementia Drugs Market, by Route Of Administration
12.1. Introduction
12.2. Oral
12.3. Transdermal
13. Dementia Drugs Market, by Patient Age Group
13.1. Introduction
13.2. 65 To 74
13.3. 75 To 84
13.4. 85 And Above
13.5. Under 65
14. Dementia Drugs Market, by Disease Stage
14.1. Introduction
14.2. Mild
14.3. Moderate
14.4. Severe
15. Dementia Drugs Market, by Patent Status
15.1. Introduction
15.2. Branded
15.3. Generic
16. Americas Dementia Drugs Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Dementia Drugs Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Dementia Drugs Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Biogen Inc.
19.3.2. Eisai Co., Ltd.
19.3.3. Eli Lilly and Company
19.3.4. Roche Holding AG
19.3.5. Novartis AG
19.3.6. H. Lundbeck A/S
19.3.7. AC Immune SA
19.3.8. Axsome Therapeutics, Inc.
19.3.9. Cassava Sciences, Inc.
19.3.10. Otsuka Pharmaceutical Co., Ltd.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. DEMENTIA DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DEMENTIA DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DEMENTIA DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DEMENTIA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL AND MEMANTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. CANADA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. CANADA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 73. CANADA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 74. CANADA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. CANADA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CANADA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. CANADA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 80. CANADA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 140. GERMANY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 141. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. GERMANY DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. GERMANY DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. GERMANY DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. GERMANY DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 146. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 147. GERMANY DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 151. FRANCE DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. FRANCE DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. FRANCE DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. FRANCE DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. FRANCE DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 158. FRANCE DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 170. ITALY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. ITALY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. ITALY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 173. ITALY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 174. ITALY DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. ITALY DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. ITALY DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. ITALY DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. ITALY DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. ITALY DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 180. ITALY DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. SPAIN DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 185. SPAIN DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SPAIN DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. SPAIN DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. SPAIN DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. SPAIN DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 190. SPAIN DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 191. SPAIN DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 228. DENMARK DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. DENMARK DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. DENMARK DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. DENMARK DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. DENMARK DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. DENMARK DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 235. DENMARK DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 247. QATAR DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. QATAR DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. QATAR DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 250. QATAR DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 251. QATAR DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. QATAR DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. QATAR DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. QATAR DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. QATAR DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 256. QATAR DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 257. QATAR DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 258. FINLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. FINLAND DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 261. FINLAND DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 262. FINLAND DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. FINLAND DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. FINLAND DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. FINLAND DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. FINLAND DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. FINLAND DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 268. FINLAND DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 294. EGYPT DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 295. EGYPT DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. EGYPT DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. EGYPT DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. EGYPT DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. EGYPT DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. EGYPT DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 301. EGYPT DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 302. TURKEY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. TURKEY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 305. TURKEY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 306. TURKEY DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. TURKEY DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. TURKEY DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 309. TURKEY DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. TURKEY DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 311. TURKEY DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 312. TURKEY DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 324. NORWAY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 325. NORWAY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 326. NORWAY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 327. NORWAY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 328. NORWAY DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. NORWAY DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. NORWAY DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 331. NORWAY DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 332. NORWAY DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. NORWAY DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 334. NORWAY DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 335. POLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 336. POLAND DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 337. POLAND DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 338. POLAND DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 339. POLAND DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 340. POLAND DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. POLAND DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 342. POLAND DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 343. POLAND DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 344. POLAND DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 345. POLAND DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 346. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 347. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Dementia Drugs market report include:
  • Biogen Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Roche Holding AG
  • Novartis AG
  • H. Lundbeck A/S
  • AC Immune SA
  • Axsome Therapeutics, Inc.
  • Cassava Sciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.6 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dementia Treatment Market Size, Share & Trends Analysis Report by Indication, Drug Class, Route of Administration (Oral, Transdermal Patch, Injectable), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Dementia Treatment Market Size, Share & Trends Analysis Report by Indication, Drug Class, Route of Administration (Oral, Transdermal Patch, Injectable), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2025-2033 - Product Image

Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From
Lewy Body Dementia Treatment Market by Treatment Modality, Distribution Channel, End User, Route of Administration, Treatment Line - Global Forecast to 2030 - Product Image

Lewy Body Dementia Treatment Market by Treatment Modality, Distribution Channel, End User, Route of Administration, Treatment Line - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Dementia Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Dementia Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 100 Pages
  • Global
From
Dementia Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Dementia Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 125 Pages
  • Global
From

About the Dementia Drug Market

The Dementia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Dementia drugs are used to treat the cognitive decline associated with Alzheimer's disease, vascular dementia, and other forms of dementia. These drugs are typically prescribed to improve memory, thinking, and behavior, as well as to slow the progression of the disease. Common dementia drugs include cholinesterase inhibitors, memantine, and glutamate modulators. Some companies in the Dementia Drug market include Pfizer, Novartis, Merck, and Eli Lilly. Other companies include Biogen, AstraZeneca, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.